Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

NCT02289209 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Head and Neck Cancer
Carcinoma, Squamous Cell of Head and Neck

Interventions

RADIATION: Reirradiation
DRUG: MK-3475

Sponsor

Dan Zandberg

Collaborators

[object Object]